Core Insights - Abbott missed third-quarter revenue estimates due to weaknesses in its diagnostics and nutrition businesses, despite strong demand for medical devices [1][3] - The company is facing challenges from declining COVID-19 testing demand, new U.S. tariffs, and a freeze on foreign aid [1] Financial Performance - Total revenue for the quarter ended September 30 was $11.37 billion, slightly below analysts' estimate of $11.40 billion [3] - Adjusted profit per share was reported at $1.30, aligning with analysts' expectations [5] - Annual adjusted profit is now expected to be between $5.12 and $5.18 per share, a slight adjustment from the previous range of $5.10 to $5.20 [5] Business Segments - The medical devices segment outperformed estimates, driven by sales of heart devices and continuous glucose monitors [3] - The nutrition business, particularly the pediatric division, faced challenges due to competition and lawsuits related to its specialized formula for premature infants [4] Market Conditions - The diagnostics division is experiencing pricing pressure from China's procurement program, which purchases medical devices at significant discounts [2] - CEO Robert Ford indicated that growth in China is around 5% to 7% when excluding the diagnostics segment [2] - Current headwinds are viewed by RBC Capital Markets analysts as "transitory" [2][3] Regulatory Impact - Abbott expects a financial hit of under $200 million from current tariffs this year but does not anticipate a significant impact from the Section 232 probes into medical device imports [5]